Solriamfetol hydrochloride

Solriamfetol Hydrochloride is a pharmaceutical drug used in the treatment of sleep disorders, specifically narcolepsy and obstructive sleep apnea (OSA). It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and is marketed under the brand name Sunosi by Jazz Pharmaceuticals.

Pharmacology

Solriamfetol hydrochloride acts as a norepinephrine-dopamine reuptake inhibitor (NDRI), increasing the levels of these neurotransmitters in the brain. This action helps to promote wakefulness and reduce excessive daytime sleepiness. Unlike other stimulants, solriamfetol does not directly stimulate the release of these neurotransmitters but instead inhibits their reuptake, leading to increased concentrations in the synaptic cleft.

Clinical Use

Solriamfetol hydrochloride is used in the treatment of narcolepsy and obstructive sleep apnea (OSA). It is indicated for patients who experience excessive daytime sleepiness as a result of these conditions. The drug is typically administered once daily in the morning and is available in tablet form.

Side Effects

Common side effects of solriamfetol hydrochloride include headache, nausea, decreased appetite, and insomnia. More serious side effects can include high blood pressure and heart rate, psychiatric symptoms, and the potential for abuse or dependence.

History

Solriamfetol hydrochloride was approved by the Food and Drug Administration (FDA) in 2019. It was developed by Jazz Pharmaceuticals, a biopharmaceutical company based in Ireland.

See Also

• Narcolepsy
• Obstructive sleep apnea
• Norepinephrine-dopamine reuptake inhibitor
• Jazz Pharmaceuticals
• Food and Drug Administration